News
Nathan Arboleda, BS; John B. Miller, MD; Ines Laíns, MD, PhD; Deeba Husain, MD; and Patrick Oellers, MD
Intravitreal injection of VEGF antagonists is the accepted gold standard for the management of neovascular (exudativ…
Eric K. Chin, MD; and David R.P. Almeida, MD, MBA, PhD
Clinical trials now under way or recently completed have the potential to make new therapeutic options available soo…
Michael Ammar, MD; and Jason Hsu, MD
It is tempting to observe the retina therapeutics and pharmacology pipeline the way we watch a horse race -- which c…
Pravin U. Dugel, MD
The names of new drugs, studies, and companies fly around at retina meetings. It can be difficult to keep the names …
Priyatham (Prithu) S. Mettu, MD
The inaugural Future is Now: Leaders in Ocular Gene Therapy Meeting, focusing on gene therapy in ophthalmology, took…
Kourous A. Rezaei, MD
Telemedicine is on the rise. Today, the landscape of telemedicine ranges from remote patient consultations to handhe…
John B. Miller, MD; and Rebecca Zeng, BA; With Sidebar Commentary by Judy E. Kim, MD
There is no doubt that anti-VEGF therapy has revolutionized care for individuals w
Jeffrey S. Heier, MD; Allen C. Ho, MD; and Robert L. Avery, MD
